Page last updated: 2024-12-06

azalanstat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Azalanstat is a small molecule inhibitor of the enzyme HDAC6, a histone deacetylase. It has been investigated for its potential therapeutic effects in various conditions, including cancer, neurodegenerative diseases, and inflammatory disorders. Azalanstat has shown promise in preclinical studies, demonstrating anti-cancer activity by inducing apoptosis and inhibiting tumor growth. It has also shown neuroprotective effects in animal models of neurodegenerative diseases. The compound is currently being evaluated in clinical trials for its safety and efficacy in treating cancer and other diseases. Research into azalanstat focuses on understanding its mechanism of action, identifying potential targets, and developing strategies to improve its therapeutic potential.'

azalanstat: inhibits lanosterol 14 alpha-demethylase, the enzyme which catalyzes the first step in conversion of lanosterol to cholesterol in mammals; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60876
CHEMBL ID70611
SCHEMBL ID1230519
MeSH IDM0219604

Synonyms (23)

Synonym
bdbm50044424
4-(((2s,4s)-2-((1h-imidazol-1-yl)methyl)-2-(4-chlorophenethyl)-1,3-dioxolan-4-yl)methylthio)benzenamine
4-{(2s,4s)-2-[2-(4-chloro-phenyl)-ethyl]-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethylsulfanyl}-phenylamine
unii-2nl79ni1ws
2nl79ni1ws ,
azalanstat [inn]
azalanstat
CHEMBL70611 ,
4-[[(2s,4s)-2-[2-(4-chlorophenyl)ethyl]-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]aniline
benzenamine, 4-(((2-(2-(4-chlorophenyl)ethyl)-2-(1h-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methyl)thio)-, (2s-cis)-
rs 21607
rs-21607
143393-27-5
1-(((2s,4s)-4-(((p-aminophenyl)thio)methyl)-2-(p-chlorophenethyl)-1,3-dioxolan-2-yl)methyl)imidazole
rs-21607197
gtpl8799
compound 1 [pmid: 8340925]
SCHEMBL1230519
Q4832127
4-((((2s,4s)-2-((1h-imidazol-1-yl)methyl)-2-(4-chlorophenethyl)-1,3-dioxolan-4-yl)methyl)thio)aniline
DTXSID401029427
azalanstat free base
AKOS040746604
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Steroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)Ki1.03600.03800.39691.6250AID161640; AID51625
Heme oxygenase 1 Rattus norvegicus (Norway rat)IC50 (µMol)5.30001.10004.320010.0000AID1832399
Cytochrome P450 3A4Homo sapiens (human)Ki0.02800.00011.41629.9000AID161642
AromataseHomo sapiens (human)Ki0.00760.00000.60469.5010AID54200
Cytochrome P450 11B1, mitochondrialHomo sapiens (human)Ki0.03500.03500.03500.0350AID51047
Heme oxygenase 2Rattus norvegicus (Norway rat)IC50 (µMol)25.88001.10004.483310.0000AID1832398; AID241681; AID267293; AID287886; AID764734
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
steroid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
androgen biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
glucocorticoid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
sex differentiationSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
steroid metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
hormone biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
progesterone metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
C21-steroid hormone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
immune responseCytochrome P450 11B1, mitochondrialHomo sapiens (human)
regulation of blood pressureCytochrome P450 11B1, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucose homeostasisCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
steroid 17-alpha-monooxygenase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
iron ion bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
oxygen bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
heme bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
17-alpha-hydroxyprogesterone aldolase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
steroid 11-beta-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
endoplasmic reticulumSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
endoplasmic reticulum membraneSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
axonSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
neuronal cell bodySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
mitochondrionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1832399Inhibition of Sprague-Dawley rat spleen microsome HO-1 assessed as bilirubin formation incubated for 60 mins by double-beam spectrophotometry2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
AID241716In vitro inhibitory concentration against heme oxygenase 1 from rat spleen2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors.
AID54200Binding affinity for Cytochrome P450 19A11993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID85689Percentage lowering of the total serum cholesterol in male hamsters at a dose of 10 mg/dL orally administered for 14 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID287885Inhibition of Sprague-Dawley rat spleen microsome HO12007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring.
AID86732Inhibition of lanosterol 14-alpha-demethylation in hepatic microsomes from human1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID85818Percentage lowering of the total serum cholesterol in male hamsters at a dose of 50 mg/dL orally administered for 14 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID267292Inhibition of Sprague-Dawley rat spleen HO12006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.
AID85817Percentage lowering of the total serum cholesterol in male hamsters at a dose of 5 mg/dL orally administered for 14 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID287886Inhibition of Sprague-Dawley rat brain microsome HO22007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring.
AID287887Selectivity index, ratio of IC50 for Sprague-Dawley rat brain HO2 to IC50 for Sprague-Dawley rat spleen HO12007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring.
AID1832398Inhibition of Sprague-Dawley rat brain microsome HO-2 assessed as bilirubin formation incubated for 60 mins by double-beam spectrophotometry2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
AID83865Effect on total serum cholesterol in male hamsters at a dose of 50 mg/kg orally administered for 14 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID1353892Inhibition of HO-2 in Sprague-Dawley albino rat brain microsomes assessed as reduction in bilirubin formation using hemin as substrate after 60 mins in presence of NADPH by biliverdin reductase enzyme coupled spectrophotometric assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors.
AID1422093Inhibition of heme oxygenase 1 in Sprague-Dawley rat spleen microsomal fraction assessed as decrease in bilirubin formation using biliverdin reductase as substrate after 60 mins by spectrophotometric method2018European journal of medicinal chemistry, Oct-05, Volume: 158Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
AID85816Percentage lowering of the total serum cholesterol in male hamsters at a dose of 30 mg/dL orally administered for 3 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID1353891Inhibition of HO-1 in Sprague-Dawley albino rat spleen microsomes assessed as reduction in bilirubin formation using hemin as substrate after 60 mins in presence of NADPH by biliverdin reductase enzyme coupled spectrophotometric assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors.
AID244387Relative binding affinity to rat heme oxygenases 1 and 22005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors.
AID51047Binding affinity for corticoid 11-beta-hydroxylase1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID51625Binding affinity for cholesterol 17-alpha-hydroxylase1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID1832401Selectivity index, ratio of IC50 for inhibition of Sprague-Dawley rat brain microsome HO-2 to IC50 for inhibition of Sprague-Dawley rat spleen microsome HO-12021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
AID83862Effect on total serum cholesterol in male hamsters at a dose of 25 mg/kg orally administered for 14 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID764734Inhibition of Sprague-Dawley rat brain HO-2 assessed as bilirubin formation after 60 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID267293Inhibition of Sprague-Dawley rat brain HO22006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.
AID83857Effect on total serum cholesterol in male hamsters at a dose of 10 mg/kg orally administered for 3 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID83863Effect on total serum cholesterol in male hamsters at a dose of 30 mg/kg orally administered for 3 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID89415Inhibition of cellular cholesterol biosynthesis using human fibroblasts in tissue culture1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID85815Percentage lowering of the total serum cholesterol in male hamsters at a dose of 25 mg/dL orally administered for 14 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID161642Binding affinity for progesterone 6-beta-hydroxylase of hepatic microsomes1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID83856Effect on total serum cholesterol in male hamsters at a dose of 10 mg/kg orally administered for 14 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID86733Inhibition of lanosterol 14-alpha-demethylation in hepatic microsomes from rat1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID83864Effect on total serum cholesterol in male hamsters at a dose of 5 mg/kg orally administered for 14 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID1353893Selectivity index, ratio of IC50 for HO-2 in Sprague-Dawley albino rat brain microsomes to IC50 for HO-1 in Sprague-Dawley albino rat spleen microsomes2018European journal of medicinal chemistry, Mar-25, Volume: 148Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors.
AID85690Percentage lowering of the total serum cholesterol in male hamsters at a dose of 10 mg/dL orally administered for 3 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID764735Inhibition of Sprague-Dawley rat spleen microsomal HO-1 assessed as bilirubin formation after 60 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID86731Inhibition of lanosterol 14-alpha-demethylation in hepatic microsomes from hamster1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID83859Effect on total serum cholesterol in male hamsters at a dose of 100 mg/kg orally administered for 3 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID241681In vitro inhibitory concentration against heme oxygenase 2 from rat brain2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors.
AID267294Selectivity index, rat HO2/HO12006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.
AID85812Percentage lowering of the total serum cholesterol in male hamsters at a dose of 100 mg/dL orally administered for 3 days1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID161640Binding affinity for progesterone 17-alpha,20-lyase1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID1345280Human CYP19A1 (CYP11, CYP17, CYP19, CYP20 and CYP21 families)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
AID1345279Human CYP51A1 (CYP39, CYP46 and CYP51 families)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (22.22)18.2507
2000's8 (44.44)29.6817
2010's5 (27.78)24.3611
2020's1 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]